Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170737 | 0.79 | — | — | |
| SCHEMBL2420759 | 0.77 | MCL1 (0.34) | MCL1 | |
| SCHEMBL11447784 | 0.77 | — | — | |
| SCHEMBL6748118 | 0.77 | LMNA (0.41) | MCL1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL4334239 | 0.76 | MGAM (0.35) | LMNA | |
| SCHEMBL10396862 | 0.75 | MCL1 (0.37) | MCL1ALDH1A1 | |
| SCHEMBL1421343 | 0.75 | — | — | |
| SCHEMBL28416408 | 0.75 | — | — | |
| SCHEMBL22321687 | 0.75 | MCL1 (0.37) | MCL1 | |
| SCHEMBL28913780 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086927-B1 | IMINIUM SALTS AND METHODS OF PREPARING ELECTRON DEFICIENT OLEFINS USING SUCH NOVEL IMINIUM SALTS | LOCTITE R & D LTD (IE) | 2013-02-27 | — | — | EP | disclosed |
| US-8022251-B2 | Iminium salts and methods of preparing electron deficient olefins using such novel iminium salts | LOCTITE (R&D) LIMITED (IE) | 2011-09-20 | — | — | US | disclosed |
| US-20090203934-A1 | NOVEL IMINIUM SALTS AND METHODS OF PREPARING ELECTRON DEFICIENT OLEFINS USING SUCH NOVEL IMINIUM SALTS | LOCTITE (R&D) LIMITED (IE) | 2009-08-13 | — | — | US | disclosed |
| EP-2086927-A1 | IMINIUM SALTS AND METHODS OF PREPARING ELECTRON DEFICIENT OLEFINS USING SUCH NOVEL IMINIUM SALTS | Loctite (R & D) Limited (IE) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008050313-A1 | IMINIUM SALTS AND METHODS OF PREPARING ELECTRON DEFICIENT OLEFINS USING SUCH NOVEL IMINIUM SALTS | LOCTITE (R & D) LIMITED (IE) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203934-A1 | NOVEL IMINIUM SALTS AND METHODS OF PREPARING ELECTRON DEFICIENT OLEFINS USING SUCH NOVEL IMINIUM SALTS | IDH2, MACF1, LIG4 | MCL1 2684/4885KDM4E 1681/4885ALDH1A1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.